A pooled analysis of the KEYNOTE-001, -010, -024, and -042 trials demonstrated a clear survival advantage of pembrolizumab over chemotherapy in patients with PD-L1–positive NSCLC and BMs. This evidence concerns the gene CD274 and non-small cell lung carcinoma.